Innate Pharma (IPHA) Receivables - Net (2017 - 2025)

Innate Pharma (IPHA) has disclosed Receivables - Net for 8 consecutive years, with $5.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables - Net fell 91.11% year-over-year to $5.3 million, compared with a TTM value of $5.3 million through Dec 2024, down 91.11%, and an annual FY2024 reading of $5.4 million, down 91.05% over the prior year.
  • Receivables - Net was $5.3 million for Q4 2024 at Innate Pharma, down from $59.8 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $59.8 million in Q4 2023 and bottomed at $3.1 million in Q4 2022.
  • Average Receivables - Net over 5 years is $23.1 million, with a median of $21.1 million recorded in 2021.
  • The sharpest move saw Receivables - Net surged 1802.26% in 2023, then tumbled 91.11% in 2024.
  • Year by year, Receivables - Net stood at $26.0 million in 2020, then dropped by 18.98% to $21.1 million in 2021, then plummeted by 85.09% to $3.1 million in 2022, then soared by 1802.26% to $59.8 million in 2023, then crashed by 91.11% to $5.3 million in 2024.
  • Business Quant data shows Receivables - Net for IPHA at $5.3 million in Q4 2024, $59.8 million in Q4 2023, and $3.1 million in Q4 2022.